BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 25694410)

  • 1. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
    McBride A; Klaus JO; Stockerl-Goldstein K
    Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
    Bilotti E
    Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
    Vij R; Siegel DS; Jagannath S; Jakubowiak AJ; Stewart AK; McDonagh K; Bahlis N; Belch A; Kunkel LA; Wear S; Wong AF; Wang M
    Br J Haematol; 2012 Sep; 158(6):739-48. PubMed ID: 22845873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
    Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
    Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
    Jagannath S; Vij R; Stewart AK; Trudel S; Jakubowiak AJ; Reiman T; Somlo G; Bahlis N; Lonial S; Kunkel LA; Wong A; Orlowski RZ; Siegel DS
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):310-8. PubMed ID: 23040437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib for the treatment of multiple myeloma.
    Lue J; Goel S; Mazumder A
    Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
    Jakubowiak AJ
    Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib: a novel second-generation proteasome inhibitor.
    Khan ML; Stewart AK
    Future Oncol; 2011 May; 7(5):607-12. PubMed ID: 21568676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
    J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib in multiple myeloma.
    Andreu-Vieyra C; Berenson JR
    Expert Opin Biol Ther; 2014 Nov; 14(11):1685-99. PubMed ID: 25170966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Nooka AK
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():11-8. PubMed ID: 25184231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A practical review on carfilzomib in multiple myeloma.
    Muchtar E; Gertz MA; Magen H
    Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma.
    McCormack PL
    Drugs; 2012 Oct; 72(15):2023-32. PubMed ID: 22994535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
    Hobeika L; Self SE; Velez JC
    BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.